Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
BUSINESS
Mikitani Resolved to Grow Rakuten Medical into Global Biotech
Hiroshi Mikitani, chairman and CEO of Rakuten Medical, expressed his determination on July 1 to groom the company into a globally recognized biotech firm that can go it alone in running end-to-end operations from the R&D of drugs and medical…
To read the full story
Related Article
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
- Rakuten Medical Gears Up for Global Pitch on Photoimmunotherapy: Chairman
August 4, 2023
- Rakuten Medical’s Photoimmunotherapy Now Available in Japan
February 9, 2021
- After Photoimmunotherapy Nod, Rakuten’s Mikitani Says Company Is Finally at Start Line
September 30, 2020
- Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
July 1, 2020
- Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
BUSINESS
- Daiichi Sankyo to Promote COO Okuzawa to CEO
January 31, 2025
- Sarepta Drops DMD Drug Patent Claim against Nippon Shinyaku in Japan
January 31, 2025
- Novo Launches Once-Weekly Insulin Awiqli in Japan
January 31, 2025
- J&J Files Nipocalimab for Generalized Myasthenia Gravis in Japan
January 31, 2025
- Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…